nemu

HOME > NEWS

NEWS

AskAt Inc. Announces EP4 Antagonist Oncology and Auto-Immune Diseases Partnership with Ningbo Tai Kang Medical Technology Co., Ltd.

2016/12/19

December 19, 2016 – AskAt Inc. (AskAt), headquartered in Nagoya, Japan, today announced license agreements with Ningbo Tai Kang Medical Technology Co., Ltd (Ningbo Tai Kang), headquartered in Ningbo, Zhejiang, People’s Republic of China (China), President: Weiyue Han, granting Ningbo Tai Kang exclusive rights to develop, manufacture and commercialize AskAt’s EP4 Antagonist [AAT-007] in China for Oncology and Auto-Immune Diseases. Under the terms of the signed agreements, AskAt will receive upfront payments from Ningbo Tai Kang and is eligible to receive Development and Commercial Milestone payments and Royalties on sales of products in China.

 

Ningbo Tai Kang is a VC-backed biotech company and focus to develop innovative medicine for China and North Asia, including Japan/Korea as well. The focused key disease areas for Ningbo Tai Kang are pain, infectious diseases, and oncology which has highly unmet medical needs.

PAGE TOP

Menu